{"organizations": [], "uuid": "600106a12a229d3c9b2794f4a818b1eca45edcb6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/pfizer-fda/fda-approves-pfizers-xeljanz-to-treat-ulcerative-colitis-idUSL3N1T15DS", "country": "US", "domain_rank": 408, "title": "FDA approves Pfizer's Xeljanz to treat ulcerative colitis", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-30T19:08:00.000+03:00", "replies_count": 0, "uuid": "600106a12a229d3c9b2794f4a818b1eca45edcb6"}, "author": "", "url": "https://www.reuters.com/article/pfizer-fda/fda-approves-pfizers-xeljanz-to-treat-ulcerative-colitis-idUSL3N1T15DS", "ord_in_thread": 0, "title": "FDA approves Pfizer's Xeljanz to treat ulcerative colitis", "locations": [], "entities": {"persons": [{"name": "manas mishra", "sentiment": "none"}, {"name": "xeljanz", "sentiment": "none"}, {"name": "shounak dasgupta", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "pfizer", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "pfizer inc", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 30, 2018 / 4:08 PM / Updated 8 minutes ago FDA approves Pfizer's Xeljanz to treat ulcerative colitis Reuters Staff 1 Min Read\nMay 30 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Pfizer Incâ€™s drug Xeljanz to treat adults with moderately to severely active ulcerative colitis, making it the first oral drug to be approved for chronic use in such patients.\nXeljanz is already approved by the FDA to treat rheumatoid arthritis and psoriatic arthritis.\nUlcerative colitis is a chronic, inflammatory bowel disease affecting the colon and causing recurrent flares of abdominal pain and bloody diarrhea.\nMore than 900,000 patients are affected with the disease in the United States, according to the FDA. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)", "external_links": [], "published": "2018-05-30T19:08:00.000+03:00", "crawled": "2018-05-30T19:21:18.002+03:00", "highlightTitle": ""}